Gx Works 2 1.98 86: Enhance Your Coordination with Factory Automation Devices

Compounds that are inhibitors or inducers of CYP3A would be expected to increase or decrease plasma alprazolam concentrations, respectively. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.66 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS]. Other studied drugs include:

• PermittedFor non-commercial purposes:Read, print & download

• Text & data mine

• Translate the article

• Not PermittedReuse portions or extracts from the article in other works

• Redistribute or republish the final article

• Sell or re-use for commercial purposes

Elsevier's open access license policy

Gx Works 2 1.98 86

Download Zip

2ff7e9595c